Starting Jan. 1, the list price for Wegovy, Ozempic and Rybelsus, Novo's semaglutide products, will be $675 across the board in the U.S.
This reduction represents a 50 percent cut for oral and injectable Wegovy, with current list prices of $1,349.02. It's a 34 percent cut for Ozempic and Ryeblsus, which are both now priced at $1,027.51.
"Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's U.S. operation, said in a statement.
Due to high demand and interest, Novo has sought avenues to make its blockbuster line of semglutide products available at lower prices, launching direct-to-consumer portals and collaborations with telemedicine platforms to offer the drug without the autoinjector.
Federal government pressures to lower prices have also come into play.
The Centers for Medicare and Medicaid Services (CMS) selected semaglutide for Medicare negotiations last year. In November, CMS unveiled it had negotiated a 71 percent discount on a 30-day supply of semaglutide for Medicare, going from $959 to $274. These prices are scheduled to go into effect at the start of 2027.
The Trump administration additionally pushed several companies, including Novo, to enter into "most favored nation" (MFN) drug pricing agreements last year, with manufacturers agreeing to sell their GLP-1 injectables for a monthly starting price starting of $245 for people on Medicare and Medicaid.
When TrumpRx was launched earlier this month, Ozempic and Wegovy were among the first few dozen drugs offered on the platform, offering coupons hovering around 80 percent off the list price.
A spokesperson for Novo Nordisk told The Hill that this slash in costs is unrelated to the company's MFN agreement with the administration.
No comments:
Post a Comment